NTT DATA Strengthens Global Insurance Leadership with Acquisition of Alchemy Technology Services
21.10.2025 10:00:00 CEST | Business Wire | Press Release
NTT DATA, a global leader in AI, digital business and technology services, today announced the acquisition of Alchemy Technology Services, a specialist insurance technology consultancy. The move reinforces NTT DATA’s commitment to transforming the global insurance ecosystem, addressing current and emerging challenges around agility, modernization and scalability. In addition to its strong consultancy and Guidewire credentials, Alchemy brings deep expertise in the specialty insurance market, particularly in supporting complex and regulated environments, such as the London Market, the largest (re)insurance subscription market globally. This will further strengthen NTT DATA’s ability to serve niche and high-value segments across the global insurance landscape.
A shared vision for insurance innovation
This acquisition marks a significant milestone in NTT DATA’s strategy to lead the digital reinvention of the insurance sector - a market set to reach $230.7 billion in IT spend this year.
Building on its strong foundation in the industry, NTT DATA’s insurance capabilities are driven by a network of more than 15,000 specialists operating in 26 countries worldwide. With over 300 clients worldwide, the company serves 6 of top 10 insurers by revenues.
By combining its global scale and expertise with Alchemy’s strong foundation and local roots, NTT DATA is uniquely positioned to address the evolving needs of insurers worldwide.
The integration will accelerate core modernization efforts with agility and scalability, support the digital transformation of key markets and foster a smarter, more connected and data-driven approach to insurance. Together, the companies will co-innovate around emerging technologies including AI, automation, sustainability and next-generation insurance products.
Enhanced value and empowered talent
The acquisition delivers enhanced value to insurance clients through expanded capabilities in core system implementation, digital transformation, testing and application management. It also strengthens NTT DATA’s regional presence in the UK and Ireland, offering dedicated expertise across the full insurance lifecycle.
The Alchemy team will serve as a Global Centre of Excellence, helping shape and deliver complex transformation programs for insurers worldwide. Alchemy’s unique delivery model will be adopted internationally, with its academy training approach extended to support teams in other global locations.
Alchemy’s pioneering training model, which has developed over 200 professionals since 2018, will be further empowered under NTT DATA’s leadership.
A unified future
NTT DATA and Alchemy are committed to a collaborative, transparent and authentic integration process. The partnership is built on shared values of teamwork, development and innovation, with a focus on delivering positive change for clients, employees and the broader insurance community.
Bruno Abril, Global Lead, Insurance Industry, NTT DATA, Inc. said:“Joining forces with Alchemy enhances our ability to accelerate digital transformation in the insurance industry, reinforcing our strategic growth ambitions and the vast opportunities we see ahead. IT modernization in P&C insurance is not a fleeting trend - it’s a core market priority attracting sustained investment. Together, we are uniquely positioned to lead this transformation. This acquisition is a natural evolution of our shared vision, complementary capabilities and aligned values, empowering us to deliver smarter, scalable solutions that meet the evolving needs of insurers worldwide.”
John Harkin, Founder and CEO of Alchemy, said: “This is a proud and exciting moment for our team, our clients, and the wider region. Becoming part of NTT DATA unlocks extraordinary opportunities, not just for international growth, but for expanding the reach and impact of the work we do. As someone deeply committed to the north-west of Ireland, I’m especially proud that this move allows us to reaffirm and strengthen our long-term commitment to the area.”
Will McAllister, Senior Vice President, Managing Director, EMEA at Guidewire Software, welcomed the announcement: “We are delighted to hear the news of Alchemy’s acquisition by NTT DATA. This marks an exciting milestone, which we believe will open even greater opportunities to transform the global insurance industry. As a longstanding partner, we look forward to continuing to work together to deliver innovative solutions and even greater value for clients.”
About NTT DATA
NTT DATA is a $30+ billion business and technology services leader, serving 75% of the Fortune Global 100. We are committed to accelerating client success and positively impacting society through responsible innovation. We are one of the world’s leading AI and digital infrastructure providers, with unmatched capabilities in enterprise-scale AI, cloud, security, connectivity, data centers and application services. Our consulting and industry solutions help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have experts in more than 50 countries. We also offer clients access to a robust ecosystem of innovation centers as well as established and start-up partners. NTT DATA is part of NTT Group, which invests over $3 billion each year in R&D.
Visit us at nttdata.com
About Alchemy Technology Services
Founded in 2018, Alchemy Technology Services is a specialist in digital transformation and consultancy services for the global insurance industry. The company is a Guidewire Advantage Partner, delivering solutions across core platform implementations, upgrades, testing, and cloud adoption. Headquartered in Northern Ireland, Alchemy also has a presence in London following its acquisition of a UK-based insurance technology firm in 2023. The company is known for its agile approach, client-first ethos and investment in talent development through its bespoke academy model.
Alchemy plays a key role in the commercial and London Market, offering strategic consultancy and implementation support for insurers operating in complex, regulated environments. This focus aligns closely with NTT DATA’s investment in London and its ambition to scale within global insurance hubs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251021527943/en/
Contacts
Media contact:
Marian Scala: marian.scala@global.ntt
Ed Jones-Davies: ed.jonesdavies@hotwireglobal.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom